Mangrove Partners Bluebird Bio, Inc. Transaction History

Mangrove Partners

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$4.07 - $10.6 $695,103 - $1.81 Million	-170,787 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$8.96 - $16.31 $43,008 - $78,288	-4,800 Reduced 2.73%	170,787 $1.71 Million
Q3 2021 Nov 15, 2021	BUY	$11.24 - $21.0 $274,413 - $512,694	24,414 Added 16.15%	175,587 $3.36 Million
Q2 2021 Aug 16, 2021	SELL	$18.04 - $22.09 $3.16 Million - $3.87 Million	-175,178 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$18.04 - $22.09 $2.73 Million - $3.34 Million	151,173 New	151,173 $4.84 Million
Q1 2021 May 17, 2021	BUY	$16.59 - $33.89 $2.91 Million - $5.94 Million	175,178 New	175,178 $5.28 Million
Q4 2020 Feb 16, 2021	SELL	$27.5 - $37.92 $7.78 Million - $10.7 Million	-283,087 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$34.44 - $43.75 $5.29 Million - $6.71 Million	153,465 Added 118.39%	283,087 $15.3 Million
Q2 2020 Aug 14, 2020	BUY	$27.12 - $45.97 $3.52 Million - $5.96 Million	129,622 New	129,622 $7.91 Million

159

79.5M

525K

634K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $31.6M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Mangrove Partners, based on Form 13F filings with the SEC.

Stay updated on Mangrove Partners with notifications on news.